Cargando…

Synthesis of Biocompatible and Environmentally Nanofibrous Mats Loaded with Moxifloxacin as a Model Drug for Biomedical Applications

Biopolymeric chitosan structure (Cs) is rationally investigated owing to its potentiality in pharmaceutical applications. The synthetic routes of biomimetic Cs-based blend electrospun nanofibers were studied. Herein, biocompatible crosslinked electrospun polyvinyl alcohol (PVA)/Cs-reduced gold nanop...

Descripción completa

Detalles Bibliográficos
Autores principales: Teaima, Mahmoud H., Abdelnaby, Fatma A., Fadel, Maha, El-Nabarawi, Mohamed A., Shoueir, Kamel R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693921/
https://www.ncbi.nlm.nih.gov/pubmed/33126627
http://dx.doi.org/10.3390/pharmaceutics12111029
_version_ 1783614857422045184
author Teaima, Mahmoud H.
Abdelnaby, Fatma A.
Fadel, Maha
El-Nabarawi, Mohamed A.
Shoueir, Kamel R.
author_facet Teaima, Mahmoud H.
Abdelnaby, Fatma A.
Fadel, Maha
El-Nabarawi, Mohamed A.
Shoueir, Kamel R.
author_sort Teaima, Mahmoud H.
collection PubMed
description Biopolymeric chitosan structure (Cs) is rationally investigated owing to its potentiality in pharmaceutical applications. The synthetic routes of biomimetic Cs-based blend electrospun nanofibers were studied. Herein, biocompatible crosslinked electrospun polyvinyl alcohol (PVA)/Cs-reduced gold nanoparticles (Cs(Rg))/β-CD (beta-cyclodextrin) in pure water were fabricated. To this end, supportive PVA as a carrier, Cs bio modifier, and gold reductant and β-CD as smoother, inclusion guest molecule, and capping agent exhibit efficient entrapment of moxifloxacin (Mox) and consequently accelerate release. Besides, PVA/Cs(Rg)/β-CD paves towards controlled drug encapsulation-release affinity, antimicrobial, and for wound dressing. Without losing the nanofiber structure, the webs prolonged stability for particle size and release content up to 96.4%. The synergistic effect of the nanoformulation PVA/Cs(Rg)/β-CD against pathogenic bacteria, fungus, and yeast, including Staphylococcus aureus, Escherichia coli, Candida albicans, and Aspergillus niger, posed clear zones up to 53 φmm. Furthermore, a certain combination of PVA/Cs (Rg)/β-CD showed a total antioxidant capacity of 311.10 ± 2.86 mg AAE/g sample. In vitro cytotoxicity assay of HePG2 and MCF-7 NF6 can eradicate 34.8 and 29.3 µg/mL against selected cells.
format Online
Article
Text
id pubmed-7693921
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-76939212020-11-28 Synthesis of Biocompatible and Environmentally Nanofibrous Mats Loaded with Moxifloxacin as a Model Drug for Biomedical Applications Teaima, Mahmoud H. Abdelnaby, Fatma A. Fadel, Maha El-Nabarawi, Mohamed A. Shoueir, Kamel R. Pharmaceutics Article Biopolymeric chitosan structure (Cs) is rationally investigated owing to its potentiality in pharmaceutical applications. The synthetic routes of biomimetic Cs-based blend electrospun nanofibers were studied. Herein, biocompatible crosslinked electrospun polyvinyl alcohol (PVA)/Cs-reduced gold nanoparticles (Cs(Rg))/β-CD (beta-cyclodextrin) in pure water were fabricated. To this end, supportive PVA as a carrier, Cs bio modifier, and gold reductant and β-CD as smoother, inclusion guest molecule, and capping agent exhibit efficient entrapment of moxifloxacin (Mox) and consequently accelerate release. Besides, PVA/Cs(Rg)/β-CD paves towards controlled drug encapsulation-release affinity, antimicrobial, and for wound dressing. Without losing the nanofiber structure, the webs prolonged stability for particle size and release content up to 96.4%. The synergistic effect of the nanoformulation PVA/Cs(Rg)/β-CD against pathogenic bacteria, fungus, and yeast, including Staphylococcus aureus, Escherichia coli, Candida albicans, and Aspergillus niger, posed clear zones up to 53 φmm. Furthermore, a certain combination of PVA/Cs (Rg)/β-CD showed a total antioxidant capacity of 311.10 ± 2.86 mg AAE/g sample. In vitro cytotoxicity assay of HePG2 and MCF-7 NF6 can eradicate 34.8 and 29.3 µg/mL against selected cells. MDPI 2020-10-28 /pmc/articles/PMC7693921/ /pubmed/33126627 http://dx.doi.org/10.3390/pharmaceutics12111029 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Teaima, Mahmoud H.
Abdelnaby, Fatma A.
Fadel, Maha
El-Nabarawi, Mohamed A.
Shoueir, Kamel R.
Synthesis of Biocompatible and Environmentally Nanofibrous Mats Loaded with Moxifloxacin as a Model Drug for Biomedical Applications
title Synthesis of Biocompatible and Environmentally Nanofibrous Mats Loaded with Moxifloxacin as a Model Drug for Biomedical Applications
title_full Synthesis of Biocompatible and Environmentally Nanofibrous Mats Loaded with Moxifloxacin as a Model Drug for Biomedical Applications
title_fullStr Synthesis of Biocompatible and Environmentally Nanofibrous Mats Loaded with Moxifloxacin as a Model Drug for Biomedical Applications
title_full_unstemmed Synthesis of Biocompatible and Environmentally Nanofibrous Mats Loaded with Moxifloxacin as a Model Drug for Biomedical Applications
title_short Synthesis of Biocompatible and Environmentally Nanofibrous Mats Loaded with Moxifloxacin as a Model Drug for Biomedical Applications
title_sort synthesis of biocompatible and environmentally nanofibrous mats loaded with moxifloxacin as a model drug for biomedical applications
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693921/
https://www.ncbi.nlm.nih.gov/pubmed/33126627
http://dx.doi.org/10.3390/pharmaceutics12111029
work_keys_str_mv AT teaimamahmoudh synthesisofbiocompatibleandenvironmentallynanofibrousmatsloadedwithmoxifloxacinasamodeldrugforbiomedicalapplications
AT abdelnabyfatmaa synthesisofbiocompatibleandenvironmentallynanofibrousmatsloadedwithmoxifloxacinasamodeldrugforbiomedicalapplications
AT fadelmaha synthesisofbiocompatibleandenvironmentallynanofibrousmatsloadedwithmoxifloxacinasamodeldrugforbiomedicalapplications
AT elnabarawimohameda synthesisofbiocompatibleandenvironmentallynanofibrousmatsloadedwithmoxifloxacinasamodeldrugforbiomedicalapplications
AT shoueirkamelr synthesisofbiocompatibleandenvironmentallynanofibrousmatsloadedwithmoxifloxacinasamodeldrugforbiomedicalapplications